COMPLETED

Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)

NCT02300532•Eisai Co., Ltd.

Summary

Post-marketing surveillance to investigate the clinical safety and effectiveness in patients of all implantation of Gliadel with malignant glioma in the actual medical setting.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•All-patient of Gliadel implantation

Exclusion Criteria

•None

Locations (2)

Osaka, Osaka, Japan

Tokyo, Tokyo, Japan

Key Dates

Start Date

January 10, 2013

Primary Completion Date

July 10, 2014

Completion Date

March 24, 2015

Last Updated

February 27, 2017

Enrollment

561

ACTUAL participants

Conditions

Malignant Glioma

Interventions

No intervention

OTHER

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

NCT05099003

Malignant Glioma

View study

RECRUITINGEARLY_PHASE1

Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma

NCT05717153

Diffuse GliomaMalignant Glioma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 27, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

ACTIVE_NOT_RECRUITING

PHASE1